Imperial College London
Portrait Picture

Dr Oliver (OJ) Watson

Faculty of Medicine, School of Public Health

Lecturer
 
 
 
//

Contact

 

o.watson15

 
 
//

Location

 

Translation & Innovation Hub BuildingWhite City Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Watson:2021:10.1101/2021.04.08.437876,
author = {Watson, OJ and Gao, B and Nguyen, TD and Tran, TN-A and Penny, MA and Smith, DL and Okell, L and Aguas, R and Boni, MF},
doi = {10.1101/2021.04.08.437876},
title = {Pre-existing partner-drug resistance facilitates the emergence and spread of artemisinin resistance: a consensus modelling study},
url = {http://dx.doi.org/10.1101/2021.04.08.437876},
year = {2021}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - <jats:title>Abstract</jats:title><jats:sec><jats:title>Background</jats:title><jats:p>Artemisinin-resistant genotypes have now emerged a minimum of five times on three continents despite recommendations that all artemisinins be deployed as artemisinin combination therapies (ACTs). Widespread resistance to the non-artemisinin partner drugs in ACTs has the potential to limit the clinical and resistance benefits provided by combination therapy.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>Using a consensus modelling approach with three individual-based mathematical models of <jats:italic>Plasmodium falciparum</jats:italic> transmission, we evaluate the effects of pre-existing partner-drug resistance and ACT deployment on artemisinin resistance evolution. We evaluate settings where dihydroartemisinin-piperaquine (DHA-PPQ), artesunate-amodiaquine (ASAQ), or artemether-lumefantrine (AL) are deployed as first-line therapy. We use time until 0.25 artemisinin resistance allele frequency (the establishment time) as the primary outcome measure.</jats:p></jats:sec><jats:sec><jats:title>Findings</jats:title><jats:p>Higher frequencies of pre-existing partner-drug resistant genotypes lead to earlier establishment of artemisinin resistance. Across all scenarios and pre-existing frequencies of partner-drug resistance explored, a 0.10 increase in partner-drug resistance frequency on average corresponded to 0.7 to 5.0 years loss of artemisinin efficacy. However, the majority of reductions in time to artemisinin establishment were observed after the first increment from 0.0 to 0.10 partner-drug resistance genotype frequency.</jats:p></jats:sec><jats:sec><jats:title>Interpretation</jats:title><jats:p>Partner-drug resistance in ACTs facilitates the early emergence of artemisinin resistance and is a major public
AU  - Watson,OJ
AU  - Gao,B
AU  - Nguyen,TD
AU  - Tran,TN-A
AU  - Penny,MA
AU  - Smith,DL
AU  - Okell,L
AU  - Aguas,R
AU  - Boni,MF
DO  - 10.1101/2021.04.08.437876
PY  - 2021///
TI  - Pre-existing partner-drug resistance facilitates the emergence and spread of artemisinin resistance: a consensus modelling study
UR  - http://dx.doi.org/10.1101/2021.04.08.437876
ER  -
Download